根据白血病和淋巴瘤协会（LLS）的数据，弥漫性大B细胞淋巴瘤（DLBCL）是最常见的侵袭性非霍奇金淋巴瘤（NHL）亚型。 纪念斯隆-凯特琳癌症中心的研究人员在临床前研究中发现伊布替尼与HDAC抑制剂分别针对BCR通路上布鲁顿酪氨酸激酶（BTK）和MyD88-激发NF-kB活化的双重靶向抑制，在体外和体内均对MyD88突变、ABC-亚型DLBCL产生了协同的抗肿瘤活性。

艾贝司他是一款新型组蛋白去乙酰化酶抑制剂（HDAC），正在开展治疗非霍奇金淋巴瘤(NHL)和肾细胞癌全球关键性临床试验。 伊布替尼（IMBRUVICA®）是杨森，艾伯维和Pharmacyclics LLC联合开发首创BTK抑制剂，已批准用于多种血液系统恶性肿瘤和慢性移植物抗宿主病（cGVHD）。

关于徐诺药业

徐诺药业是一家专注于肿瘤药物开发的生物制药公司。徐诺药业目前的产品管线主要包括三款候选药物。公司拥有这些药物的全球独家开发、生产和商业化权益。其领先的候选药物艾贝司他正在进行治疗肾细胞癌（与培唑帕尼联用）和单药治疗非霍奇金淋巴瘤的全球关键临床试验。徐诺药业另外一款临床阶段候选药物为可进入临床2期的XP-105（BI 860585），这是一个ATP竞争性的mTORC1 / 2抑制剂，对多种实体瘤有效。徐诺药业的临床前候选药物XP-102（BI 882370）是一个治疗结肠直肠癌和黑色素瘤的泛-RAF抑制剂。

Use of Forward-Looking Statements

This press release contains “forward-looking” statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions.  Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Xynomic has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related Xynomic’s financial position and need for additional capital to complete the planned trials and support its continuing operation, risks related to uncertainty in maintaining and obtaining regulatory approval and ultimately commercialize its drug candidates or delays in doing so; and the risks more fully described in Xynomic’s Prospectus (file No. 333-229127) and other filings that Xynomic may make with the SEC in the future. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

投资者关系、媒体和商务拓展请联系：

angela.feng@xynomicpharma.com